Cancer Cells Hide from Antibody-Drug Conjugates by Blocking Internalization
Researchers uncover how cancer cells evade ADC therapy by suppressing drug uptake — and identify a drug target to reverse resistance.
Summary
Antibody-drug conjugates (ADCs) like enfortumab vedotin are promising cancer treatments, but many tumors develop resistance. This study found that some resistant cancer cells still display the target protein on their surface but block the drug from being absorbed inside the cell. The culprit is a protein called AKR1C1, which interferes with the normal cellular machinery that pulls the ADC inward and also helps shuttle the drug back out of cells via tiny secreted particles. Blocking AKR1C1 with existing drugs restored drug uptake and improved treatment effectiveness in lab models. These findings reveal a new and clinically important resistance mechanism and suggest that combining AKR1C1 inhibitors with ADC therapy could overcome treatment failure in patients who appear to still express the target but stop responding.
Detailed Summary
Antibody-drug conjugates represent one of oncology's most exciting advances, linking a targeting antibody to a cytotoxic payload to kill cancer cells precisely. Enfortumab vedotin, which targets the cell-surface protein NECTIN4, has shown strong results in urothelial carcinoma. However, a significant proportion of patients either do not respond initially or develop resistance over time, limiting long-term benefit.
To understand how resistance arises, researchers at Sun Yat-sen University Cancer Center used a sophisticated combination of approaches: spatial transcriptomics on matched tumor samples collected before and after treatment, single-cell RNA sequencing, humanized mouse models, and resistant cell line systems. This enabled them to map how tumor cell states shift under ADC therapy pressure.
They identified a paradoxical resistant population: cells with high NECTIN4 surface expression — meaning the drug can still bind — but defective internalization of the ADC complex. This 'target-high, uptake-defective' state is caused by AKR1C1, a metabolic enzyme that physically binds NECTIN4 and disrupts the clathrin-mediated endocytosis pathway normally responsible for bringing bound ADCs inside the cell. Additionally, the AKR1C1-WWP2 protein axis promotes secretion of the ADC payload via extracellular vesicles, further depleting intracellular drug levels.
Critically, pharmacologic inhibition of AKR1C1 in preclinical models reversed these defects, restoring ADC internalization and enhancing tumor cell killing. This points to AKR1C1 inhibition as a tractable strategy to re-sensitize resistant tumors.
These findings have important clinical implications: standard resistance monitoring focuses on target antigen loss, but this study shows tumors can evade ADCs while maintaining surface target expression. Biomarker testing for AKR1C1 status and membrane trafficking defects could refine patient selection and guide combination therapy strategies. The main caveat is that findings remain preclinical, and translation to patients requires clinical validation.
Key Findings
- Resistant cancer cells retain NECTIN4 surface expression but block ADC internalization, evading drug delivery.
- AKR1C1 protein disrupts clathrin-mediated endocytosis of NECTIN4-ADC complexes, impairing payload uptake.
- The AKR1C1-WWP2 axis exports ADC payload via extracellular vesicles, further reducing intracellular drug accumulation.
- Pharmacologic AKR1C1 inhibition restores ADC uptake and re-sensitizes resistant tumors in preclinical models.
- A 'target-high but uptake-defective' resistance state is a clinically relevant, previously underappreciated resistance mechanism.
Methodology
The study integrated spatial transcriptomics from paired pre- and post-treatment tumor biopsies, single-cell RNA sequencing, humanized mouse models, and in vitro resistant cell line systems. This multi-modal approach allowed characterization of tumor-state remodeling during ADC resistance development. Mechanistic findings were validated through functional inhibition experiments in preclinical models.
Study Limitations
All mechanistic and therapeutic findings are based on preclinical models; clinical validation in patients is required before practice change. The summary is based on the abstract only, as the full text was not accessible. The generalizability of the AKR1C1-mediated resistance mechanism to other ADC targets and cancer types beyond urothelial carcinoma remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.